By Fineline Cube Gilead Sciences, Inc. (NASDAQ: GILD) and Merck & Co., Inc. (MSD; NYSE: MRK) announced that detailed outcomes from the Phase 3 ISLEND-1 (NCT06630286) and ISLEND-2 (NCT06630299) trials will be presented for the first time at the 26th International AIDS Conference (AIDS 2026). The trials evaluated the investigational once-weekly oral single-tablet regimen of islatravir 2 mg/lenacapavir 300 mg (ISL/LEN) for HIV treatment.
Clinical Trial Overview
| Item | Detail |
|---|---|
| Trials | ISLEND-1 (NCT06630286) and ISLEND-2 (NCT06630299) |
| Phase | Phase 3 |
| Patient Population | Adults living with HIV who were virologically suppressed |
| Comparator Arms | ISLEND-1: BIKTARVY® (bictegravir/emtricitabine/tenofovir alafenamide); ISLEND-2: Other standard-of-care daily oral regimens |
| Primary Endpoint | Week 48 efficacy results |
| Presentation Venue | 26th International AIDS Conference (AIDS 2026) |
| Regimen | Once-weekly oral single-tablet (islatravir 2 mg/lenacapavir 300 mg) |
Investigational Combination Profile
Islatravir (MSD)
- Class: Next-generation nucleoside analog
- Mechanism: Multiple mechanisms of action including HIV-1 reverse transcriptase translocation inhibition
- Developer: Merck & Co., Inc. (MSD)
Lenacapavir (Gilead)
- Class: First-in-class capsid inhibitor
- Mechanism: Disrupts HIV-1 at multiple stages of its lifecycle
- Developer: Gilead Sciences, Inc.
Combination Advantages
- Dosing: Complete once-weekly oral tablet enabled by favorable potency and pharmacokinetic profiles
- Convenience: Significant reduction in dosing frequency compared to current daily regimens
- Adherence: Potential to improve long-term treatment adherence through simplified dosing
Key Efficacy Results
- ISLEND-1: ISL/LEN demonstrated non-inferior efficacy compared to BIKTARVY, a global guideline-recommended standard of care
- ISLEND-2: ISL/LEN showed comparable efficacy to other standard-of-care oral daily antiretroviral regimens
- Patient Population: Both trials enrolled adults who were virologically suppressed at baseline and switched to the investigational regimen
Safety Profile
The safety profile of ISL/LEN was generally similar to the comparator regimens studied in both ISLEND trials. No new safety concerns were identified during the 48-week treatment period, supporting the favorable risk-benefit profile of the once-weekly regimen.
Strategic Collaboration Impact
This collaboration between two pharmaceutical giants represents a significant advancement in HIV treatment paradigms. If approved, ISL/LEN would be the first once-weekly oral complete regimen for HIV treatment, potentially transforming the standard of care and addressing a critical unmet need for simplified, long-acting treatment options.
Market Context
Current HIV treatment requires daily oral medication, which can impact long-term adherence and quality of life. The development of long-acting regimens has been a major focus of the HIV therapeutic landscape, with previous advances limited to injectable formulations requiring clinical administration.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial results, regulatory approvals, and commercial expectations. Actual results may differ due to risks including regulatory decisions, competitive dynamics, and market acceptance.-Fineline Info & Tech